乌司奴单抗对克罗恩病临床缓解及透壁愈合的疗效

doi:10.19723/j.issn.1671-167X.2024.02.008

摘要/Abstract

摘要：

目的: 应用乌司奴单抗(ustekinumab, UST)治疗克罗恩病(Crohn’s disease, CD)患者，评估临床及内镜缓解情况，采用肠道超声(intestinal ultrasonography, IUS)评估透壁应答(transmural response, TR)与透壁愈合(transmural healing, TH)情况。方法: 回顾性分析2020年1月到2022年8月北京大学人民医院所有确诊应用UST进行治疗的CD患者，分别于治疗后8周、治疗后16/20周进行评估，包括临床、生化学指标、结肠镜及IUS检查。结果: 共纳入患者13例，其中男性11例，女性2例，平均年龄36.92岁，治疗前Best克罗恩病活动指数(Best Crohn’s disease activity index, Best CDAI)平均值为270.12±105.55。在治疗8周时，患者的Best CDAI评分下降至133.16± 48.66 (t=4.977，P＜0.001)，8例患者达到临床缓解，5例未达到临床缓解。共有9例患者治疗前后进行结肠镜检查评估，治疗前进行简化克罗恩病内镜下评分(simple endoscopic score for Crohn’s disease，SES-CD)，评分为10.71± 7.14，16/20周复查SES-CD下降至6.00±7.81(t=2.483，P=0.048)，其中4例患者达到内镜缓解，5例患者未达到内镜缓解。在8周时，13例患者中有5例达到TR，2例达到TH，6例未达到TR或TH。16/20周时，6例患者达到TR，3例达到TH，4例未达到TR或TH。UST对于小肠和结肠病变的TR效果差异无统计学意义(Fisher精确概率检验，P＞0.999)。既往应用过其他生物制剂的患者中UST的TR偏低，但差异无统计学意义(Fisher精确概率检验，P=0.491)。结论: 应用UST 16/20周后患者的临床情况及内镜下评估均有改善，部分患者可以达到临床缓解及内镜缓解；UST对CD患者具有较好的TR效果，在8周即出现TR，16/20周TR有所增加；UST对小肠和结肠病变的TR效果差异无统计学意义；既往未应用过其他生物制剂的患者UST的TR较既往使用过生物制剂的患者效果更好，但差异无统计学意义。

关键词: 克罗恩病, 乌司奴单抗, 透壁应答, 透壁愈合

Abstract:

Objective: To treat the Crohn's disease (CD) patients with ustekinumab (UST), to eva-luate their clinical and endoscopic remission, and to evaluate their transmural response (TR) and transmural healing (TH) condition using intestinal ultrasonography (IUS). Methods: Retrospective analysis was made on patients diagnosed with CD in Peking University People's Hospital from January 2020 to August 2022, who were treated with UST for remission induction and maintenance therapy. All the patients were evaluated on both week 8 and week 16/20 after treatment, including clinical, biochemical indicators, colonoscopy and IUS examination. Results: A total of 13 patients were enrolled in this study, including 11 males and 2 females. The minimum age was 23 years, the maximum age was 73 years and the mean age was 36.92 years. All the patients were in the active stage of disease before treatment, and the average Best Crohn's disease activity index (Best CDAI) score was 270.12±105.55. In week 8, the Best CDAI score of the patients decreased from 270.12±105.55 to 133.16±48.66 (t=4.977, P < 0.001). Eight patients achieved clinical remission while 5 patients remained in the active stage. Nine patients underwent colonoscopy evaluation. The average simple endoscopic score for Crohn's disease (SES-CD) score decreased from 10.71±7.14 before treatment to 6.00±7.81(t=2.483, P=0.048) in week 16/20. Four patients achieved endoscopic remission while 5 patients did not. In week 8, 5 patients achieved TR, 2 patients achieved TH, the other 6 patients did not get TR or TH. In week 16/20, 6 patients achieved TR, 3 patients achieved TH while the other 4 patients did not get TR or TH. There was no significant statistical difference in the TR effect of UST between small intestine and colon lesions (Fisher test, P > 0.999). The rate of UST transmural response in the patients who had had previous biological agent therapy was lower than those with no previous biological agent therapy, but there was no significant statistical difference (Fisher test, P=0.491). Conclusion: After treatment of UST, the clinical and endoscopic conditions of the CD patients had been improved, and some patients could achieve clinical remission and endoscopic remission. UST had good TR and TH effects on CD. TR might appear in week 8, and the TR effect increased in week 16/20. There was no significant statistical difference in the TR effect between small intestine and colon lesions. TR effect of UST was better in the patients who had no previous biological agent therapy than those who had had other biological agents, but the result had no significant statistical difference.

Key words: Crohn's disease, Ustekinumab, Transmural response, Transmural healing

中图分类号:

R574.1

吴芸,徐亚兰,张国艳,张媛媛,王峻瑶,尤鹏,彭涛,刘玉兰,陈宁. 乌司奴单抗对克罗恩病临床缓解及透壁愈合的疗效[J]. 北京大学学报（医学版）, 2024, 56(2): 253-259.

Yun WU,Yalan XU,Guoyan ZHANG,Yuanyuan ZHANG,Junyao WANG,Peng YOU,Tao PENG,Yulan LIU,Ning CHEN. Clinical remission and transmural healing of ustekinumab in patients with Crohn's disease[J]. Journal of Peking University (Health Sciences), 2024, 56(2): 253-259.

图/表 4

图1

图2

图3

图4

参考文献 20

1	Torres J , Mehandru S , Colombel JF , et al. Crohn's disease[J]. Lancet, 2017, 389 (10080): 1741- 1755. doi: 10.1016/S0140-6736(16)31711-1
2	Geyl S , Guillo L , Laurent V , et al. Transmural healing as a therapeutic goal in Crohn's disease: A systematic review[J]. Lancet Gastroenterol Hepatol, 2021, 6 (8): 659- 667. doi: 10.1016/S2468-1253(21)00096-0
3	Helwig U , Fischer I , Hammer L , et al. Transmural response and transmural healing defined by intestinal ultrasound: New potential therapeutic targets?[J]. J Crohns Colitis, 2022, 16 (1): 57- 67. doi: 10.1093/ecco-jcc/jjab106
4	Best WR , Becktel JM , Singleton JW , et al. Development of a Crohn's disease activity index. National cooperative Crohn's disease study[J]. Gastroenterology, 1976, 70 (3): 439- 444. doi: 10.1016/S0016-5085(76)80163-1
5	Lu C , Merrill C , Medellin A , et al. Bowel ultrasound state of the art: Grayscale and doppler ultrasound, contrast enhancement, and elastography in Crohn disease[J]. J Ultrasound Med, 2019, 38 (2): 271- 288. doi: 10.1002/jum.14920
6	Laserna-Mendieta EJ , Lucendo J . Faecal calprotectin in inflammatory bowel diseases: A review focused on meta-analyses and routine usage limitations[J]. Clin Chem Lab Med, 2019, 57 (9): 1295- 1307. doi: 10.1515/cclm-2018-1063
7	Solem CA , Loftus EJ , Tremaine WJ , et al. Correlation of C-reactive protein with clinical, endoscopic, histologic, and radiographic activity in inflammatory bowel disease[J]. Inflamm Bowel Dis, 2005, 11 (8): 707- 712. doi: 10.1097/01.MIB.0000173271.18319.53
8	Schnitzler F , Fidder H , Ferrante M , et al. Mucosal healing predicts long-term outcome of maintenance therapy with infliximab in Crohn's disease[J]. Inflamm Bowel Dis, 2009, 15 (9): 1295- 1301. doi: 10.1002/ibd.20927
9	Turner D , Ricciuto A , Lewis A , et al. STRIDE-Ⅱ: An update on the selecting therapeutic targets in inflammatory bowel disease (STRIDE) initiative of the international organization for the study of IBD (IOIBD): Determining therapeutic goals for treat-to-target strategies in IBD[J]. Gastroenterology, 2021, 160 (5): 1570- 1583. doi: 10.1053/j.gastro.2020.12.031
10	Mazzuoli S , Guglielmi FW , Antonelli E , et al. Definition and evaluation of mucosal healing in clinical practice[J]. Dig Liver Dis, 2013, 45 (12): 969- 977. doi: 10.1016/j.dld.2013.06.010
11	Civitelli F , Nuti F , Oliva S , et al. Looking beyond mucosal hea-ling: Effect of biologic therapy on transmural healing in pediatric Crohn's disease[J]. Inflamm Bowel Dis, 2016, 22 (10): 2418- 2424. doi: 10.1097/MIB.0000000000000897
12	Zacharopoulou E , Craviotto V , Fiorino G , et al. Targeting the gut layers in Crohn's disease: Mucosal or transmural healing?[J]. Expert Rev Gastroenterol Hepatol, 2020, 14 (9): 775- 787. doi: 10.1080/17474124.2020.1780914
13	Lafeuille P , Hordonneau C , Vignette J , et al. Transmural healing and MRI healing are associated with lower risk of bowel damage progression than endoscopic mucosal healing in Crohn's disease[J]. Aliment Pharmacol Ther, 2021, 53 (5): 577- 586. doi: 10.1111/apt.16232
14	Sandborn WJ , Rebuck R , Wang Y , et al. Five-year efficacy and safety of ustekinumab treatment in Crohn's disease: The IMUNITI trial[J]. Clin Gastroenterol Hepatol, 2022, 20 (3): 578- 590. doi: 10.1016/j.cgh.2021.02.025
15	Yao J Y , Zhang M , Wang W , et al. Ustekinumab trough concentration affects clinical and endoscopic outcomes in patients with refractory Crohn's disease: A Chinese real-world study[J]. BMC Gastroenterol, 2021, 21 (1): 380. doi: 10.1186/s12876-021-01946-8
16	Kucharzik T , Wilkens R , D'Agostino MA , et al. Early ultrasound response and progressive transmural remission after treatment with ustekinumab in Crohn's disease[J]. Clin Gastroenterol Hepatol, 2023, 21 (1): 153- 163. doi: 10.1016/j.cgh.2022.05.055
17	Calabrese E , Rispo A , Zorzi F , et al. Ultrasonography tight control and monitoring in Crohn's disease during different biological therapies: A multicenter study[J]. Clin Gastroenterol Hepatol, 2022, 20 (4): e711- e722. doi: 10.1016/j.cgh.2021.03.030
18	Feagan BG , Rubin DT , Danese S , et al. Efficacy of vedolizumab induction and maintenance therapy in patients with ulcerative colitis, regardless of prior exposure to tumor necrosis factor antagonists[J]. Clin Gastroenterol Hepatol, 2017, 15 (2): 229- 239. doi: 10.1016/j.cgh.2016.08.044
19	Hanauer SB , Sandborn WJ , Feagan BG , et al. IM-UNITI: Three-year efficacy, safety, and immunogenicity of ustekinumab treatment of Crohn's disease[J]. J Crohns Colitis, 2020, 14 (1): 23- 32. doi: 10.1093/ecco-jcc/jjz110
20	Ghosh S , Gensler LS , Yang Z , et al. Ustekinumab safety in psoriasis, psoriatic arthritis, and Crohn's disease: An integrated analysis of phase Ⅱ/Ⅲ clinical development programs[J]. Drug Saf, 2019, 42 (6): 751- 768. doi: 10.1007/s40264-019-00797-3

Metrics

Viewed

Full text

Abstract

Cited

Shared

Discussed

[1]	贺冰洁,刘志科,沈鹏,孙烨祥,陈彬,詹思延,林鸿波. 2011—2020年宁波市鄞州区炎症性肠病发病的流行病学研究[J]. 北京大学学报（医学版）, 2022, 54(3): 511-519.
[2]	周吴平,穆楠,简伟研,王化虹. 克罗恩病患者疾病经济负担现状与相关因素[J]. 北京大学学报（医学版）, 2021, 53(3): 555-559.